Venkat Nimmagadda, MD
Nephrology · Dothan, ALNPI 1043267917
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Akebia Therapeutics Inc accounts for 82.4% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $5,039, more than ten times the $60 reported in 2019.
Across 45 payments — averaging $124.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$5K
- AstraZeneca$248
- Fresenius USA Marketing, Inc.$147
- Aurinia Pharma U.S., Inc.$129
- Medtronic$123
- Travere Therapeutics, Inc.$63
- plus $277 from 9 others
What the payments were for
- Speaking & faculty fees$3,22557%
- Travel & lodging$77614%
- Food & beverage$1,58228%
- Education$341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 15 | $4,629 |
| AstraZeneca | 4 | $248 |
| Fresenius USA Marketing, Inc. | 2 | $147 |
| Aurinia Pharma U.S., Inc. | 1 | $129 |
| Medtronic | 3 | $123 |
| Travere Therapeutics, Inc. | 9 | $63 |
| Novartis | 2 | $63 |
| Vantive US Healthcare LLC | 1 | $51 |
| Amgen | 2 | $43 |
| Calliditas Therapeutics US Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $21 |
| OPKO Pharmaceuticals, LLC | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,617 in reported general payments places this provider in the 75th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 110 | $140,884 |
| JardianceEmpagliflozin | 59 | $55,406 |
| Sevelamer Carbonate | 44 | $14,783 |
| SpsSodium Polystyrene Sulfon/Sorb | 19 | $14,142 |
| Calcium Acetate | 103 | $14,005 |
| Cinacalcet Hcl | 21 | $6,248 |
| Nifedipine ErNifedipine | 184 | $5,537 |
| Bumetanide | 89 | $4,602 |
| Calcitriol | 163 | $4,474 |
| LyricaPregabalin | 12 | $3,543 |
| Midodrine Hcl | 17 | $2,780 |
| Hydralazine Hcl | 90 | $1,621 |
| Potassium Chloride | 78 | $1,302 |
| Labetalol Hcl | 14 | $993 |
| Lisinopril | 118 | $949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $248 | $140,884110 claims |
| Boehringer IngelheimJardiance | $22 | $55,40659 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 164 nephrology providers in Alabama.
Other nephrology in Dothan
- Michael QuadriniHuntsville$323K
- Dana RizkBirmingham$196K
- Sumeet MunjalMontgomery$191K
- Eric WallaceBirmingham$172K
- Phillip MadoniaAlabaster$165K
- Thomas OzbirnHomewood$133K
- David WarnockBirmingham$128K
- Jeffrey GlazeHomewood$98K
- Michal MrugBirmingham$73K
- Vineeta KumarBirmingham$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.